{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:19:00Z","timestamp":1792423140439,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients receiving daily opioid agonist treatment (OAT) for opioid dependence, several countries relaxed treatment guidelines at the beginning of the COVID-19 pandemic. This involved longer take-home intervals for methadone and buprenorphine doses as well as a reduction in supervised dosing and drug screening. To date, little is known about the medium or long-term experience of OAT deregulation. Therefore, we conducted a survey to explore how OAT providers perceived greater flexibility in OAT service delivery at the end of the second year of the pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nationwide cross-sectional study of twenty-three OAT units in 19 publicly funded hospital trusts in Norway. OAT units were sent a 29-item online questionnaire comprising closed-format and open-ended questions on treatment provider experiences and changes in OAT service delivery during the past 12 months (January to December 2021).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-three (of whom female: 14; 60.8%) managers or lead physicians of OAT units completed the questionnaire reporting that, in 2021, most OAT units (91.3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921) still practiced some adjusted approaches as established in the beginning of the pandemic. The most common adaptions were special protocols for COVID-19 cases (95.7%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), increased use of telephone- (91.3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921) and video consultations (87.0%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), and longer take-home intervals for OAT medications (52.2%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912). The use of depot buprenorphine also increased substantially during the pandemic. According to the OAT providers, most patients handled flexible treatment provision well. In individual cases, patients\u2019 substance use was identified as key factor necessitating a reintroduction of supervised dosing and drug screening. Collaboration with general practitioners and municipal health and social services was generally perceived as crucial for successful treatment delivery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, the Norwegian OAT system proved resilient in the second year of the COVID-19 pandemic, as its healthcare workforce embraced innovation in technology (telemedicine) and drug development (depot buprenorphine). According to our nationally representative sample of OAT providers, most patients were compliant with longer take-home doses of methadone and buprenorphine. Our findings suggest that telemedicine can be useful as adjunct to face-to-face treatment and provide greater flexibility for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-023-09959-7","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T09:02:34Z","timestamp":1694077354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3373-4943","authenticated-orcid":false,"given":"Rebecca","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-3634","authenticated-orcid":false,"given":"Anne Berit","family":"Bech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2421-4201","authenticated-orcid":false,"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"9959_CR1","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"9959_CR2","first-page":"CD011983","volume":"4","author":"R Saulle","year":"2017","unstructured":"Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017;4:CD011983.","journal-title":"Cochrane Database Syst Rev"},{"key":"9959_CR3","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons. 2021. Available from: https:\/\/www.emcdda.europa.eu\/publications\/adhoc-publication\/impact-covid-19-drug-markets-use-harms-and-drug-services-community-and-prisons_en. Accessed 04 Sept 2023."},{"key":"9959_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16:68.","journal-title":"Addict Sci Clin Pract"},{"key":"9959_CR5","doi-asserted-by":"publisher","first-page":"12094","DOI":"10.3390\/ijerph182212094","volume":"18","author":"D de Vargas","year":"2021","unstructured":"de Vargas D, Pereira CF, Volpato RJ, Lima AVC, da Silva Ferreira R, de Oliveira SR, et al. Strategies adopted by addiction facilities during the coronavirus pandemic to support treatment for individuals in recovery or struggling with a substance use disorder: a scoping review. Int J Environ Res Public Health. 2021;18:12094.","journal-title":"Int J Environ Res Public Health"},{"key":"9959_CR6","unstructured":"Substance Abuse And Mental Health Services Administration. Methadone take-home flexibilities extension guidance. 2020. Available from: \nhttps:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines\/methadone-guidance. (updated 3 March 2022; Accessed 24 Sep 2022)."},{"key":"9959_CR7","doi-asserted-by":"publisher","first-page":"103573","DOI":"10.1016\/j.drugpo.2021.103573","volume":"102","author":"K Corace","year":"2021","unstructured":"Corace K, Suschinsky K, Wyman J, Leece P, Cragg S, Konefal S, et al. Evaluating how has care been affected by the Ontario COVID-19 opioid agonist treatment guidance: patients\u2019 and prescribers\u2019 experiences with changes in unsupervised dosing. Int J Drug Policy. 2021;102:103573.","journal-title":"Int J Drug Policy"},{"key":"9959_CR8","doi-asserted-by":"publisher","first-page":"109049","DOI":"10.1016\/j.drugalcdep.2021.109049","volume":"228","author":"LA Goldsamt","year":"2021","unstructured":"Goldsamt LA, Rosenblum A, Appel P, Paris P, Nazia N. The impact of COVID-19 on opioid treatment programs in the United States. Drug Alcohol Depend. 2021;228:109049.","journal-title":"Drug Alcohol Depend"},{"key":"9959_CR9","doi-asserted-by":"crossref","unstructured":"Lintzeris N, Deacon RM, Hayes V, Cowan T, Mills L, Parvaresh L, et al. Opioid agonist treatment and patient outcomes during the COVID\u201019 pandemic in south east Sydney, Australia.\u00a0Drug Alcohol Rev. 2022;41(5):1009\u201319.","DOI":"10.1111\/dar.13382"},{"key":"9959_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","volume":"47","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47:722\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"9959_CR11","doi-asserted-by":"publisher","first-page":"108154","DOI":"10.1016\/j.jsat.2020.108154","volume":"119","author":"J Trujols","year":"2020","unstructured":"Trujols J, Larrabeiti A, S\u00e0nchez O, Madrid M, De Andr\u00e9s S, Duran-Sindreu S. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care? J Subst Abuse Treat. 2020;119:108154.","journal-title":"J Subst Abuse Treat"},{"key":"9959_CR12","doi-asserted-by":"publisher","first-page":"108283","DOI":"10.1016\/j.jsat.2021.108283","volume":"124","author":"SA Clark","year":"2021","unstructured":"Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, et al. Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island. J Subst Abuse Treat. 2021;124:108283.","journal-title":"J Subst Abuse Treat"},{"key":"9959_CR13","doi-asserted-by":"publisher","first-page":"108272","DOI":"10.1016\/j.jsat.2020.108272","volume":"124","author":"L Wang","year":"2021","unstructured":"Wang L, Weiss J, Ryan EB, Waldman J, Rubin S, Griffin JL. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abuse Treat. 2021;124:108272.","journal-title":"J Subst Abuse Treat"},{"key":"9959_CR14","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1097\/ADM.0000000000000809","volume":"16","author":"B Tofighi","year":"2022","unstructured":"Tofighi B, McNeely J, Walzer D, Fansiwala K, Demner A, Chaudhury CS, et al. A telemedicine buprenorphine clinic to serve New York City: Initial evaluation of the NYC public hospital system\u2019s initiative to expand treatment access during the COVID-19 pandemic. J Addict Med. 2022;16:e40\u20133.","journal-title":"J Addict Med"},{"key":"9959_CR15","volume-title":"Forebygging av Covid-19 ved LAR-foretakene i 2020 - Erfaringer og tiltak","author":"H Waal","year":"2021","unstructured":"Waal H, Lillevold PH, Welle-Strand G, Clausen T. Forebygging av Covid-19 ved LAR-foretakene i 2020 - Erfaringer og tiltak. Oslo: Senter for rus- og avhengighetsforskning, Universitetet i Oslo; 2021."},{"key":"9959_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13011-021-00395-6","volume":"16","author":"K Alexander","year":"2021","unstructured":"Alexander K, Pogorzelska-Maziarz M, Gerolamo A, Hassen N, Kelly EL, Rising KL. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021;16:60.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"9959_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1186\/s12913-022-08544-8","volume":"22","author":"L Forsgren","year":"2022","unstructured":"Forsgren L, Tediosi F, Blanchet K, Saulnier DD. Health systems resilience in practice: a scoping review to identify strategies for building resilience. BMC Health Serv Res. 2022;22:1173.","journal-title":"BMC Health Serv Res"},{"key":"9959_CR18","unstructured":"STROBE Statement. Strengthening the Reporting of Observational Studies in Epidemiology. Available from: \nhttps:\/\/strobe-statement.org\/index.php?id=strobe-home. (Accessed 11 Oct 2022)."},{"key":"9959_CR19","unstructured":"Helsedirektoratet (Norwegian Directorate of Health). Nasjonal retningslinje for legemiddelassistert rehabilitering ved opioidavhengighet (National OAT guidelines). Oslo: Helsedirektoratet; 2022. Available from: \nhttps:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-ved-opioidavhengighet. Updated 23 May 2022."},{"key":"9959_CR20","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Norway Country Drug Report. Publications of the European Union: Luxemburg. 2019. Available from: \nhttps:\/\/www.emcdda.europa.eu\/publications\/country-drug-reports\/2019\/norway_en. (Accessed 30 May 2023)."},{"key":"9959_CR21","first-page":"2022","volume-title":"Siste \u00e5r med gamle LAR-retningslinjer (OAT status report 2021)","author":"AB Bech","year":"2021","unstructured":"Bech AB, Bukten A, Lobmaier P, Skeie I, Lillevold PH, Statusrapport CT. Siste \u00e5r med gamle LAR-retningslinjer (OAT status report 2021). Oslo: Norwegian Centre for Addiction Research, University of Oslo; 2021. p. 2022."},{"key":"9959_CR22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/add.13314","volume":"111","author":"J Neale","year":"2016","unstructured":"Neale J. Iterative categorization (IC): a systematic technique for analysing qualitative data. Addiction. 2016;111:1096\u2013106.","journal-title":"Addiction"},{"key":"9959_CR23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/add.15259","volume":"116","author":"J Neale","year":"2021","unstructured":"Neale J. Iterative categorisation (IC) (part 2): interpreting qualitative data. Addiction. 2021;116:668\u201376.","journal-title":"Addiction"},{"key":"9959_CR24","doi-asserted-by":"publisher","first-page":"103787","DOI":"10.1016\/j.drugpo.2022.103787","volume":"107","author":"R McDonald","year":"2022","unstructured":"McDonald R, Eide D, Abel-Ollo K, Barnsdale L, Carter B, Clausen T, et al. A rapid assessment of take-home naloxone provision during COVID-19 in Europe. Int J Drug Policy. 2022;107:103787.","journal-title":"Int J Drug Policy"},{"key":"9959_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12913-022-07832-7","volume":"22","author":"S Bandara","year":"2022","unstructured":"Bandara S, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, et al. Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. BMC Health Serv Res. 2022;22:418.","journal-title":"BMC Health Serv Res"},{"key":"9959_CR26","volume-title":"861 brukere- om LAR i Norge","author":"G Welle-Strand","year":"2021","unstructured":"Welle-Strand G, Bj\u00f8rnestad R, Olsen IK, Pierron M. 861 brukere- om LAR i Norge. 2021."},{"key":"9959_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like 'liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18:88.","journal-title":"Harm Reduct J"},{"key":"9959_CR28","volume-title":"Balancing access to opioid substitution treatment with preventing the diversion of opioid substitution medications in Europe: challenges and implications","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2021","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Balancing access to opioid substitution treatment with preventing the diversion of opioid substitution medications in Europe: challenges and implications. Luxembourg: EMCDDA; 2021."},{"key":"9959_CR29","doi-asserted-by":"publisher","first-page":"108288","DOI":"10.1016\/j.jsat.2021.108288","volume":"124","author":"SB Hunter","year":"2021","unstructured":"Hunter SB, Dopp AR, Ober AJ, Uscher-Pines L. Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2021;124:108288.","journal-title":"J Subst Abuse Treat"},{"key":"9959_CR30","doi-asserted-by":"publisher","first-page":"109100","DOI":"10.1016\/j.drugalcdep.2021.109100","volume":"228","author":"EF Madden","year":"2021","unstructured":"Madden EF, Christian BT, Lagisetty PA, Ray BR, Sulzer SH. Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021;228:109100.","journal-title":"Drug Alcohol Depend"},{"key":"9959_CR31","doi-asserted-by":"publisher","first-page":"103877","DOI":"10.1016\/j.drugpo.2022.103877","volume":"110","author":"D Aldabergenov","year":"2022","unstructured":"Aldabergenov D, Reynolds L, Scott J, Kelleher MJ, Strang J, Copeland CS, et al. Methadone and buprenorphine-related deaths among people prescribed and not prescribed opioid agonist therapy during the COVID-19 pandemic in England. Int J Drug Policy. 2022;110:103877.","journal-title":"Int J Drug Policy"},{"key":"9959_CR32","doi-asserted-by":"publisher","first-page":"108655","DOI":"10.1016\/j.jsat.2021.108655","volume":"135","author":"MTH Harris","year":"2021","unstructured":"Harris MTH, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM. \u201cNo home to take methadone to\u201d: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. J Subst Abuse Treat. 2021;135:108655.","journal-title":"J Subst Abuse Treat"},{"key":"9959_CR33","doi-asserted-by":"publisher","first-page":"e219041","DOI":"10.1001\/jamanetworkopen.2021.9041","volume":"4","author":"N Lintzeris","year":"2021","unstructured":"Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, et al. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open. 2021;4:e219041.","journal-title":"JAMA Netw Open"},{"key":"9959_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/YCO.0000000000000795","volume":"35","author":"E Caballeria","year":"2022","unstructured":"Caballeria E, L\u00f3pez-Pelayo H, Matrai S, Gual A. Telemedicine in the treatment of addictions. Curr Opin Psychiatry. 2022;35:227\u201336.","journal-title":"Curr Opin Psychiatry"},{"key":"9959_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/ADM.0000000000000981","volume":"16","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, et al. Shifting medication treatment practices in the COVID-19 pandemic: a statewide survey of Pennsylvania Opioid Treatment Programs. J Addict Med. 2022;16:645.","journal-title":"J Addict Med"},{"key":"9959_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","volume":"43","author":"B Chan","year":"2022","unstructured":"Chan B, Bougatsos C, Priest KC, McCarty D, Grusing S, Chou R. Opioid treatment programs, telemedicine and COVID-19: a scoping review. Subst Abus. 2022;43:539\u201346.","journal-title":"Subst Abus"},{"key":"9959_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry. 2022;79:981.","journal-title":"JAMA Psychiatry"},{"key":"9959_CR38","doi-asserted-by":"publisher","first-page":"108999","DOI":"10.1016\/j.drugalcdep.2021.108999","volume":"228","author":"L Riedel","year":"2021","unstructured":"Riedel L, Uscher-Pines L, Mehrotra A, Busch AB, Barnett ML, Raja P, et al. Use of telemedicine for opioid use disorder treatment - perceptions and experiences of opioid use disorder clinicians. Drug Alcohol Depend. 2021;228:108999.","journal-title":"Drug Alcohol Depend"},{"key":"9959_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12954-021-00572-7","volume":"18","author":"SV Aronowitz","year":"2021","unstructured":"Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, Meisel Z, et al. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Harm Reduct J. 2021;18:119.","journal-title":"Harm Reduct J"},{"key":"9959_CR40","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/08897077.2022.2060447","volume":"43","author":"R Lockard","year":"2022","unstructured":"Lockard R, Priest KC, Gregg J, Buchheit BM. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Substance Abuse. 2022;43:1155\u201362.","journal-title":"Substance Abuse"},{"key":"9959_CR41","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.pec.2022.03.006","volume":"105","author":"AW Kang","year":"2022","unstructured":"Kang AW, DeBritz AA, Hoadley A, DelaCuesta C, Walton M, Hurley L, et al. Barriers and poor telephone counseling experiences among patients receiving medication for opioid use disorders. Patient Educ Couns. 2022;105:2607\u201310.","journal-title":"Patient Educ Couns"},{"key":"9959_CR42","doi-asserted-by":"publisher","first-page":"108302","DOI":"10.1016\/j.drugalcdep.2020.108302","volume":"217","author":"GK Welle-Strand","year":"2020","unstructured":"Welle-Strand GK, Skurtveit S, Clausen T, Sundal C, Gjersing L. COVID-19 survey among people who use drugs in three cities in Norway. Drug Alcohol Depend. 2020;217:108302.","journal-title":"Drug Alcohol Depend"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09959-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09959-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09959-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T07:33:51Z","timestamp":1700379231000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09959-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9959"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09959-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2212348\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Data Protection Authority (reg. number: 552107) at the University of Oslo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"965"}}